<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38501">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912222</url>
  </required_header>
  <id_info>
    <org_study_id>C16018</org_study_id>
    <nct_id>NCT01912222</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Oral MLN9708 in Cancer Patients With Liver Dysfunction</brief_title>
  <official_title>A Phase 1 Pharmacokinetic Study of Oral MLN9708 in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or
      hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate
      or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ
      Dysfunction Working Group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)</measure>
    <time_frame>Days 1 to 15 of Part A</time_frame>
    <safety_issue>No</safety_issue>
    <description>MLN9708 in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum (peak) concentration (Cmax)</measure>
    <time_frame>Days 1 to 15 of Part A</time_frame>
    <safety_issue>No</safety_issue>
    <description>MLN9708 in Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From first dose of study drug through 30 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of MLN9708.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>MLN9708 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.
Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN9708 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.
Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN9708 Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.
Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <arm_group_label>MLN9708 Arm 1</arm_group_label>
    <arm_group_label>MLN9708 Arm 2</arm_group_label>
    <arm_group_label>MLN9708 Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Patients must have a diagnosis of an advanced malignant solid tumor or hematologic
             malignancy for which standard, curative, or life-prolonging treatment does not exist
             or is no longer effective

          -  Total bilirubin and aspartate aminotransferase (AST) levels consistent with normal
             liver function (total bilirubin and AST â‰¤ the upper limit of normal), moderate
             hepatic impairment (total bilirubin &gt; 1.5 to 3x the upper limit of normal with any
             AST level) or severe hepatic impairment (total bilirubin &gt; 3x the upper limit of
             normal with any AST level)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Female patients who are postmenopausal for at least 1 year OR are surgically sterile
             OR if of childbearing potential, agree to practice 2 effective methods of
             contraception at the same time during the entire study through 90 days after the last
             dose of study drug OR agree to practice true abstinence

          -  Male patients who agree to practice effective barrier contraception during the entire
             study and through 90 days after the last dose of study drug OR agree to practice true
             abstinence

          -  Voluntary written consent

          -  Suitable venous access for the conduct of blood sampling

          -  Appropriate clinical laboratory values as specified in the protocol

        Exclusion Criteria:

          -  Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate
             inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba
             or St. John's wort within 14 days before the first dose of study drug

          -  Use of any nicotine-containing products within 14 days before the first dose of study
             drug

          -  Central Nervous System Involvement or Symptomatic brain metastasis.  Patients with
             brain metastases: must have stable neurologic status following local therapy (surgery
             or radiation) for at least 2 weeks after completion of the definitive therapy; and
             must be without neurologic dysfunction that would confound the evaluation of
             neurologic and other AEs

          -  Female patients who are lactating or breastfeeding or have a positive serum pregnancy
             test

          -  Serious medical or psychiatric illness that could interfere with participation in the
             study

          -  Treatment with any investigational products or radiotherapy within 21 days before the
             first dose of study drug

          -  Systemic anticancer therapy within 14 days before the first dose of study drug

          -  Exposure to nitrosoureas or mitomycin C within 6 weeks before the first dose of study
             drug

          -  Treatment with therapeutic monoclonal antibodies or antibody-drug conjugates within
             60 days before the first dose of study drug

          -  Radiotherapy or major surgery within the 14 days preceding the first dose of study
             drug

          -  Infection requiring systemic intravenous antibiotic therapy or other serious
             infection within 14 days before the first dose of study drug

          -  Life-threatening illness unrelated to cancer

          -  Severe CNS, pulmonary, or renal disease not related to the patient's cancer

          -  Known human immunodeficiency virus (HIV) positive

          -  Any cardiovascular condition specified in the study protocol

          -  QTc &gt; 500 milliseconds (msec) on a 12-lead ECG obtained during the Screening period

          -  Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of MLN9708

          -  Known allergy to the study medication, its analogues, or excipients in the
             formulation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center</last_name>
    <phone>1-877-674-3784</phone>
    <email>medical@mlnm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Norris</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Nemunaitis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Falchook</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
